Mycotoxins by Hendrich, Suzanne
Food Science and Human Nutrition Publications Food Science and Human Nutrition
11-2017
Mycotoxins
Suzanne Hendrich
Iowa State University, shendric@iastate.edu
Follow this and additional works at: http://lib.dr.iastate.edu/fshn_ag_pubs
Part of the Food Chemistry Commons, Food Processing Commons, and the Human and Clinical
Nutrition Commons
The complete bibliographic information for this item can be found at http://lib.dr.iastate.edu/
fshn_ag_pubs/163. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Food Science and Human Nutrition at Iowa State University Digital Repository. It has
been accepted for inclusion in Food Science and Human Nutrition Publications by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Mycotoxins
Abstract
Mycotoxins, toxins produced by fungi that commonly contaminate food crops, remain an important global
food safety concern. Aflatoxins and fumonisins mainly pose a cancer risk, whereas deoxynivalenol poses a risk
to gastrointestinal and immune function. Ochratoxin A poses a risk for kidney disease. Grains and some
legumes are the predominant sources of these toxins, but they vary in the range of foods that they
contaminate. For example, fumonisins occur mainly in corn, whereas deoxynivalenol is mainly found in
wheat, barley and corn. Aflatoxins are mainly found in peanuts and corn. The nature of the fungi that produce
each toxin seems to be the main determinant of which crop species will be the main sources of the
mycotoxins.
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18.1 INTRODUCTION 11 
Mycotoxins, toxins produced by fungi that commonly contaminate food crops, remain an 12 
important global food safety concern. Aflatoxins and fumonisins mainly pose a cancer risk, 13 
whereas deoxynivalenol poses a risk to gastrointestinal and immune function. Ochratoxin A poses 14 
a risk for kidney disease.  Grains and some legumes are the predominant sources of these toxins, 15 
but they vary in the range of foods that they contaminate.  For example, fumonisins occur mainly 16 
in corn, whereas deoxynivalenol is mainly found in wheat, barley and corn. Aflatoxins are mainly 17 
found in peanuts and corn.  The nature of the fungi that produce each toxin seems to be the main 18 
determinant of which crop species will be the main sources of the mycotoxins.   19 
Aflatoxins, most importantly aflatoxin B1 (AFB1), are produced, and named for Aspergillus 20 
flavus, but other Aspergillus species also produce aflatoxins, especially A. parasiticus. Crosses of 21 
these two fungi produce greater amounts of aflatoxins than do either parent species, but the two 22 
species are typically isolated from each other, with A. flavus infecting peanuts, corn, cottonseed 23 
and tree nuts and A. parasiticus infecting mainly peanuts 1. Aflatoxin B1 is a human liver 24 
carcinogen, and is also involved in impairing growth, development and immune function of 25 
children in regions with significant aflatoxin contamination of staple foods 2. 26 
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Fumonisins are produced by at least 15 Fusarium species, especially F. verticillioides, F. 27 
proliferatum and F. subglutinans.  These fungi are corn pathogens, causing stalk rot as well as 28 
potentially harmful levels of the predominant fumonisin, B1 in corn kernels 3.  Fumonisin B1 has 29 
been associated with human esophageal cancer and neural tube defects 3, especially in regions 30 
where corn is a staple food and where contamination of corn by this toxin is not well-recognized 31 
and managed.  In vivo studies of Fusarium mycotoxins have been reviewed recently, showing a 32 
broad array of effects across many species4. 33 
Deoxynivalenol (DON) is mainly produced by Fusarium graminearum, and also by F. culmorum 34 
5.  These fungi cause Fusarium head blight in wheat, a main source of this toxin.  Other cereals 35 
such as barley and corn, can also be significant DON sources.  DON is linked with immune 36 
dysfunction and gastroenteritis, hence its prior common name, vomitoxin6. 37 
Ochratoxins are produced by Aspergillus ochraceus, A. carbonarius and Penicillium verrucosum.  38 
A. ochraceus grows and produces ochratoxin mainly in stored grains under dry conditions and in 39 
moderate temperatures.  A. carbonarius grows in grapes, so ochratoxins may be found in wines 40 
and other grape-derived foods. P. verrucosum grows well in cooler climates, so Northern 41 
European and North American grains, especially wheat, experience ochratoxin contamination 42 
mainly  from this source 7. Ochratoxin A (OTA) is the main ochratoxin important to human 43 
health, and is associated with nephritic syndrome, but only in regions with very high exposure to 44 
OTA, such as in parts of Egypt and Sierra Leone 6. 45 
A recent casual survey of scientific literature through Pubmed indicates significant research 46 
activity, especially focused on mechanisms and mitigation of toxicity of aflatoxins and 47 
deoxynivalenol, fungal biology associated with fumonisin production, and novel detection 48 
methods for ochratoxins (Table 1).  How this pattern of research activity aligns with public health 49 
needs associated with these toxins will be discussed in summarizing key recent studies related to 50 
mycotoxin risk assessment, metabolism and mitigation.  Mycotoxigenic fungi will continue to 51 
evolve, so continual improvement of techniques to identify and assess health risks of emerging 52 
mycotoxins is needed, but is seemingly not being addressed systematically at this time. 53 
 54 
 55 
 56 
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Table 1.  Survey of recent scientific papers published in English on mycotoxins catalogued by 57 
PubMed from Jan-May 2016 58 
Mycotoxin Total 
papers 
Quanti- 
tation 
in 
foods 
Novel 
detection 
methods 
Exposure 
and risk 
assessment 
Mechanisms 
of action 
and 
mitigation 
of toxicity 
Detoxi- 
fication 
in 
foods 
Fungal  
biology 
Aflatoxins 161 26 
(15%) 
35 
(20%) 
15 (9%) 49 (28%) 17 
(10%) 
19 
(11%) 
Deoxynivalenol 91 11 
(12%) 
10 
(11%) 
4 (4%) 35 (37%) 5 (5%) 28 
(30%) 
Fumonisins 64 7 
(11%) 
13 
(20%) 
4 (6%) 16 (25%) 4 (6%) 20 
(31%) 
Ochratoxin 110 12 
(11%) 
40 
(36%) 
7 (6%) 26 (24%) 9 (8%) 16 
(15%) 
 59 
18.2 MYCOTOXIN RISK ASSESSMENT  60 
Connecting human health risks with dietary exposure to mycotoxins poses severe challenges. 61 
Outbreaks of acute illness are associated with aflatoxin B1 (aflatoxicosis causing hepatic 62 
toxicity), DON (gastroenteritis) and OTA (nephritic syndrome).  Verification of mycotoxin 63 
outbreaks requires mycotoxin analysis of grain samples verified to be of the same lot or source as 64 
ingested immediately prior to the onset of illness. Blood or urinary mycotoxin analysis and 65 
assessment of disease symptoms is also required, concomitantly.  Although numerous methods 66 
are available for mycotoxin analysis, most such methods require expensive instrumentation such 67 
as LC/MS.  Medical personnel with appropriate diagnostic expertise are also required.  Public 68 
health systems coordinating such efforts are largely lacking worldwide.  To assess cancer risk 69 
from aflatoxins and fumonisins, much longer term exposure surveillance is required.  For a 70 
genotoxic agent such as aflatoxin, exposure in early life causing genetic damage may result in 71 
much later development of cancer.  For fumonisins, chronic exposure seems to be required for its 72 
carcinogenic effects.  There is yet an incomplete understanding of human dietary exposure 73 
patterns for mycotoxins in regions where mycotoxin-related health concerns exist.  It may be that 74 
OTA causes kidney impairment at lower doses than seen in nephritic syndrome, but establishing 75 
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this as a solid connection requires multivariate analysis coordinated across human populations.  76 
Likewise, DON may impair immune and intestinal function in important but relatively subtle 77 
ways that are difficult to discern.  Increased global scientific cooperation and coordination are 78 
crucial to address these needs.  It is unfortunate that disease presence rather than disease 79 
prevention seems to drive investment in such endeavors.  Mycotoxin prevention systems that are 80 
sustainable will need to include permanent investment in agricultural practices, health 81 
surveillance, and basic and translational research.  Mitigation of human health risks from 82 
mycotoxins is ethically and practically important.  Global burden from mycotoxin-associated 83 
diseases was estimated recently at ~200,000 excess liver cancer cases per year attributable to 84 
aflatoxin. Disease burdens from fumonisin, DON and OTA remain uncertain, however likely, 85 
especially for fumonisins 6.  Effects of ingestion of combinations of mycotoxins also needs 86 
greater attention. 87 
Recent studies of dietary exposure to aflatoxin modeling intake of 3 maize foods based on 88 
aflatoxin analysis of these foods in regions of Kenya.  Eating whole kernel maize would result in 89 
a 5- to 10-fold greater exposure to aflatoxin than eating maize meal or muthokoi (dehulled and 90 
processed maize), about 300 ng aflatoxin/kg body weight.  This exposure is 1000-fold greater 91 
than noted in the US 8.  92 
In a study in Lebanon, mean aflatoxin B1 exposure was 0.63 ng/kg/d, extrapolating to an 93 
increased risk of cancer of ~ 0.05 cases/100,000 individuals9, a relatively low additional risk.  In a 94 
survey of aflatoxin intake from foods in Malaysia, mean aflatoxin intake was much greater, about 95 
30 ng/kg/d, contributing ~0.7 liver cancer cases/100,000 individuals.  With the current maximum 96 
limit for aflatoxin of 15 ppb in Malaysia, this finding indicates some need for continued vigilance 97 
in limiting intake of foods contaminated with aflatoxin above that maximum10. 98 
From the most recent French Total Diet Study, only DON exposure and not exposure to aflatoxin, 99 
fumonisin or OTA exceeded the health-based guidance value (HBGV) of estimated intake of 100 
1000 ng DON/kg/d. Only 0.5% of adults and 5% of children exceeded this estimated DON intake.  101 
Mean DON exposures were estimated at ~400 ng/kg/d for adults and ~550 ng/kg/d for children 102 
from this study 11.  This study should be seen as a model for other countries to better assess health 103 
risks from mycotoxins.   104 
A total diet study of urban Lebanese showed that mean DON intake exceeded the European Food 105 
Safety Authority’s (EFSA) HBGV (1000 ng/kg/d), at 1560 ng/kg/d, whereas mean OTA intake of 106 
4.3 ng/kg/d was 80% of EFSA’s HBGV9.  When exposure to DON was combined with exposures 107 
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to 3- and 15-Acetyl DON in a case study of 1269 individuals in Shanghai, China, mean DON 108 
exposure from these 3 forms slightly exceeded the HBGV at 1085 ng/kg/d 12.  More work on 109 
public health effects of such findings related to DON are needed. 110 
A Tunisian case control study of 69 women with breast cancer and 41 controls showed 111 
significantly greater urinary α-zearalenol in women with breast cancer, with mean concentration 112 
of 4.6 ng/mL, 3-fold greater than in controls 13.  This estrogenic metabolite of zearalenone might 113 
enhance growth of estrogen-responsive breast cancer cells.  This study suggests that it would be 114 
worth studying the extent to which urinary α-zearalenol might predict breast cancer risk.  115 
However, a recent study biomonitoring mycotoxins in Belgium showed that only one adult out of 116 
239 studied had any urinary content of α-zearalenol, and this metabolite was not detected in 117 
children (n = 155)14. The study in Belgium implies that in countries with more highly developed 118 
food safety systems, zearalenone would not pose a human breast cancer risk.  A study associating 119 
zearalenone exposure with reproductive development in 163 9-10 year old girls in New Jersey 120 
showed mean urinary α-zearalenol ten-fold less than seen in Tunisian women, and lesser breast 121 
development in girls with greater zearalenone exposure 15, suggesting an anti-estrogenic effect of 122 
the mycotoxin at these exposure levels.  It is intriguing to consider further work to investigate 123 
possible breast cancer protective effects of zearalenone at exposures similar to those noted above 124 
in Belgium or the US. 125 
18.3 MYCOTOXIN METABOLISM 126 
The metabolism of mycotoxins, by animals, bacteria associated with the gut, and by plants, may 127 
be a significant factor in mitigating health risks of these compounds, but this aspect of 128 
mycotoxins has not been incorporated directly into risk assessment or mitigation strategies.  It 129 
may be that dietary and other health habits of populations either enhance or inhibit mycotoxin 130 
detoxification.  Such possibilities will be explored in this chapter section. 131 
Among the 4 major mycotoxins, aflatoxin is known to undergo significant mammalian 132 
metabolism, both in activation to its proximate carcinogenic (mutagenic) form, aflatoxin 8,9-133 
epoxide, by cytochromes P-450 (P450) 16, and its detoxification, especially by glutathione S-134 
transferases (GSTs) to transform the epoxide site’s to a hydroxyl and a glutathione adduct 17.   135 
P450s are inducible by dietary components including flavonoids 18 and cruciferous vegetables 136 
such as broccoli and cabbage 19.  Chronic food restriction also may induce P450s 20, suggesting 137 
enhanced susceptibility to AFB1 toxicity in regions where food shortages and undernutrition are 138 
more common. Paradoxically, P450s may also be inhibited by flavonoids 21.  Some flavonoids 139 
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such as apigenin, a flavonoid in parsley, inhibited AFB1 mutagenicity in vitro mediated by the 140 
human P450 enzyme thought to be important for AFB1 activation, hCYP1A2 22. The significance 141 
of this finding for prevention of AFB1-associated human cancers remains to be determined.  142 
Several studies have shown in animal models the possible mitigation of aflatoxin toxicity and 143 
carcinogenesis by dietary alterations of its metabolism.  Marked inhibition of AFB1 144 
carcinogenesis in rainbow trout, the most sensitive species to AFB1, was shown for beta-145 
naphthoflavone (BNF) and indole-3-carbinole (a component of cruciferous vegetables) but only 146 
BNF induced P450 in this model 23. This early study illustrated the complexity of attempting to 147 
prevent AFB1 carcinogenicity by dietary components, as mediated by modulation of P450.  148 
Chickens fed 100 ppb AFB1 showed induction of P450, which was prevented by supplementation 149 
with 0.5 mg selenium (Se)/kg diet compared with 0.2 mg Se/kg, suggesting that diets containing 150 
this moderately greater amount of Se might mitigate the activation of AFB1.  This approach may 151 
be feasible to investigate as a human intervention in regions where AFB1 contamination is 152 
common.  Dietary induction of GSTs as a strategy to mitigate AFB1 carcinogenicity has been 153 
shown using a model antioxidant, oltipraz, in rats 24. Oltipraz increased production of AFB-154 
glutathione metabolites in a human clinical trial, demonstrating the feasibility of this approach 25. 155 
The identification of effective dietary inducers of GSTs that can mitigation AFB1 toxicity in 156 
humans remains to be accomplished. It has been recently proposed that strategies not involving 157 
AFB1 metabolism, such as increasing dietary chlorophyllin content, which binds to and inhibits 158 
absorption of AFB1, may be more useful to consider because altering P450s and GSTs is likely to 159 
alter metabolism of many drugs, thus making public policy recommendations about such dietary 160 
constituents highly problematic 26.     161 
DON is also metabolized by inducible biotransformation in animals.  In particular, the hydroxyls 162 
of DON are sites for addition of sulfate (by sulfotransferases, STs) or glucuronide.  163 
Glucuronidation by UDP-glucuronosyltransferases (UGTs) is favored in species possessing both 164 
types of biotransformation enzymes, based on limited data 27.  Human UGTs have less capability 165 
to form DON glucuronides than do rat UGTs in vitro, but such metabolites are the predominant 166 
urinary excretion products across species 28.  DON-3-glucuronide was shown to have negligible 167 
toxicity compared with DON in human K562 cells, consistent with the general idea in toxicology 168 
that such metabolites are detoxification products 29.  Because UGTs are highly inducible by some 169 
dietary constituents, such induction may mitigate DON toxicity in humans. Neither the extent of 170 
UGT induction nor the effect of this phenomenon on DON toxicity has been established yet in 171 
humans. 172 
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 173 
The biotransformation of DON in plants to DON glucosides, especially DON-3-glucoside (D3G) 174 
has been observed 30. Many hydroxylated secondary plant metabolites are also stored in plants in 175 
glucoside form.  This conversion of DON initially was shown to “mask” DON to its detection. 176 
Since then, D3G has been recognized as a minor but not insignificant form of DON in DON-177 
contaminated grains, constituting as much as 25% of total DON in wheat and maize 31.  D3G can 178 
be readily converted back to DON by bacterial β-glucosidases in the mammalian gut. D3G per se 179 
is practically unabsorbed, so the absorption of DON from dietary D3G would occur mainly in the 180 
ileum and colon which contain most of the bacteria in the intestine.  Enhanced presence of D3G 181 
in the diet could alter the site of intestinal toxicity.  The development of grains that have 182 
increased ability to convert DON to D3G would not be advisable unless DON de-epoxidation 183 
capacity, and hence DON detoxification were also commonly occurring.  This has been 184 
demonstrated in rats, in which the urinary excretion of D3G was 5-fold less than that seen for 185 
DON; most D3G was excreted as DON or de-epoxy DON (DOM-1) in rat feces 32.  When DON 186 
was fed to pigs as D3G, its apparent bioavailability was about two-fold less 33.  DON de-187 
epoxidation in the rumen is the main fate of DON in cattle 34, which seems to be why ruminants 188 
are relatively protected from DON toxicity.  De-epoxidation in the lower intestine of pigs is also 189 
common, but this has no protective benefit from DON toxicity because DON seems to be 190 
absorbed in the small intestine before the DON de-epoxidating bacteria can be effective 35.  191 
Likewise, in one study of French farmers, about 30% of the humans tested had DON de-192 
epoxidating activity in fecal bacteria 36. A lesser extent of this metabolism was observed in 193 
individuals from the UK 37.  De-epoxidation of DON in humans would not be expected to 194 
mitigate DON toxicity appreciably unless DON were present mainly as D3G which is not 195 
currently the case.  If we presume that DON can be rapidly and extensively converted to DON 196 
glucuronides, the DON glucuronides would be expected to be eliminated mainly in bile.  These 197 
metabolites would not be reabsorbed until they were converted back to DON by bacterial 198 
glucuronidases in the lower intestines.  At that point in DON metabolism DON might be 199 
detoxified by gut bacterial DON de-epoxidases.  It may be worth exploring the feasibility of 200 
modifying the human gut microbiome to include DON de-epoxidating bacteria in individuals who 201 
do not naturally carry such bacterial species.  Some such species have been identified and might 202 
be seen as a new class of probiotics, potentially beneficial bacteria that might be introduced into 203 
the food supply.  The need for such alteration of human gut bacteria remains to be established, 204 
and would not be a trivial process.  But if such a need were confirmed (in humans who do not 205 
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already have this metabolic capability in their gut microbiomes), standards exist for assuring the 206 
efficacy and safety of probiotic bacteria 38. 207 
Ochratoxin A (OTA) is the main ochratoxin of concern to human health.  It can be hydrolyzed by 208 
proteases to form an apparently non-toxic form, ochratoxin-alpha, and phenylalanine.  The lack of 209 
toxicity of OTA-alpha has been demonstrated in zebrafish recently 39.  The percentage of 210 
ochratoxin absorbed in humans has not been directly determined, presumably due to ethical 211 
concerns about deliberately exposing humans to this presumed carcinogen, but across several 212 
species, uptake has been estimated at ~50% of ingested dose 40.  In limited human studies, OTA-213 
alpha seemed to be the predominant urinary form of OTA. In one study, human urinary contents 214 
of OTA and OTA-alpha were about equal 41.  Pregnant women showed about 10-fold greater 215 
urinary OTA-alpha  than OTA 42, indicating seemingly greater OTA detoxification ability of 216 
pregnant women than of non-pregnant women.  Hydrolysis of OTA by microbial enzymes may 217 
be a strategy for mitigation of the mycotoxin 43, but the capability of enhancing such hydrolysis in 218 
vivo in humans remains to be determined. 219 
The metabolism of fumonisins has been shown to be virtually nil in vivo, as might be expected for 220 
these highly water-soluble, relatively large and therefore, poorly absorbable toxins.  Seemingly 221 
their water-solubility facilitates their rapid excretion and poor retention in body tissues, as has 222 
been demonstrated by studies of the fate of radio-labeled FB1 in a rodent model 44.  These 223 
compounds may be altered during some food processing reactions (e.g., addition of reducing 224 
sugars to the primary amine of FB1) and by microbial enzymes (e.g., carboxylesterase FumD) 225 
that are potentially useful in mitigating the toxins 45.  226 
In summary, it may be worth considering incorporating alteration of human/gut microbial 227 
metabolism of some mycotoxins in future mitigation strategies.  Insofar as the future may hold 228 
the ability for genetic characterization of individual biotransformation enzyme genetics and 229 
polymorphisms, and thus the prospect of tailoring diet to contain the right mix of 230 
biotransformation enzyme inducers or inhibitors depending on dietary circumstances, metabolism 231 
modification may need to be part of the defense arsenal against these toxins. 232 
18.4 MYCOTOXIN MITIGATION 233 
Mitigating the presence of mycotoxins in the human food supply is mostly about reducing 234 
mycotoxin burden in grain crops used for human food.  Significant attention is also directed 235 
toward reducing mycotoxins in the feed of livestock, for example, in the case of aflatoxin, due to 236 
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carry over of the aflatoxin metabolite AFM1 into dairy milk.  Mitigation strategies involve 237 
improving mycotoxin detection and regulation, which currently means removing from the food 238 
supply foods that exceed action, advisory or guidance levels developed by the United States (US) 239 
Food and Drug Administration (FDA). Analogous standards that may be somewhat more or less 240 
stringent exist in many countries, including the European Union (EU). An action level is 241 
mandated by FDA only for aflatoxins in the US, currently set at 20 ppb for foods for human 242 
consumption.  FDA advisory levels are set at 1 ppm for deoxynivalenol in foods for human 243 
consumption, and FDA has also provide guidance levels for fumonisins of 2-4 ppm for foods for 244 
human consumption 46.   245 
A strong research publication focus has been on innovative detection methods, but this research 246 
does not seem to be well-aligned with the needs, especially in low income countries, for rapid, 247 
accurate and inexpensive mycotoxin detection.  Mycotoxin analytical methods have been recently 248 
reviewed 47 and major constraints in this field were noted, including the varied chemistries of the 249 
mycotoxins, the need to assess multiple mycotoxins in food samples and to assure that samples 250 
are appropriately representative of the scope of possible contamination, and the need for speed 251 
and economy.  QuEChERs (quick, easy, cheap, effective, rugged and safe) technologies were also 252 
noted to be especially important in the realm of mycotoxin analysis.  Portability of analytical 253 
methods is improving, with a number of promising advances coming from the realm of 254 
nanotechnology coupled with alternatives to antibody-based mycotoxin detection.  Such 255 
alternatives include aptamers (RNA-binding) and molecular imprint polymers (MIPs).  256 
Nanomaterial sensors for mycotoxins including AFB1, DON, FB1 and OTA have been developed 257 
48.  Because many nanomaterials do not occur in nature, particular caution in assessing safety 258 
related to disposal, environmental persistence, and potential health effects on humans and 259 
ecosystems is warranted.  Spectroscopic detection coupled with chromatographic separation 260 
methods of varying types and expense remain the state-of-the-art in terms of reliability, but 261 
portability of spectroscopy is also improving 47. A few recent studies on mycotoxin detection 262 
show promise.  An aptamer-based dipstick for AFB1 was shown to have comparable detectability 263 
compared with a standard ELISA method in the ppb range, as needed for food samples.  The 264 
method took 30 min to complete, with simple solvent extraction (20% methanol) of grain samples 265 
including maize 49. An antibody-based microarray system for simultaneous detection of AFB1 266 
and FB1 was shown to be feasible and comparable to standard ELISAs in detection levels.  This 267 
method will require further validation for food samples 50.  A portable evanescent wave optical 268 
aptasensor with a reversible ligand-grafted biosensing surface was demonstrated for OTA, with 269 
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detection limit of 0.4 ppb, and OTA recoveries from powdered wheat of 89—106%, with ~15% 270 
CV.  This detection limit is sufficient to meet current regulatory policies 51, but this seemingly 271 
relatively cost-effective and reusable method will need further validation across food sources of 272 
OTA.  DON-specific nanobodies (single domain antibodies) that can mimic DON have been 273 
recently discovered and might be useful in further optimizing DON detection 52.  The adoption of 274 
the Food Safety Modernization Act (FSMA) in the US in 2011 emphasizes prevention of food 275 
contamination.  It remains to be seen how FSMA will affect mycotoxin detection, but rapid, 276 
reliable and inexpensive methods available to farmers are likely to be needed, thus promising 277 
emerging technologies such as these will be crucial. 278 
Preventing mycotoxins in the field is a burden for grain producers that currently relies on their 279 
ability to identify fungal contamination and insofar as feasible and permissible to apply 280 
appropriate fungicides. Fungicide resistance is an ongoing concern, as well as general 281 
environmental and human health concern about use of synthetic chemical fungicides, so 282 
potentially toxigenic fungi-inhibiting plants and their extracts are under investigation as 283 
alternatives 53.  Commercialization remains to be achieved; significant technical and economic 284 
barriers exist in this field of “green chemicals”.   285 
Identification and development of mycotoxin-resistant crop varieties has shown particular promise 286 
in maize, a species for which at least a few naturally occurring variants are resistant to AFB1 54.  287 
AFB1 Resistance associated proteins have been identified, and current genomic technologies may 288 
permit engineering of such proteins into other crop species.  But no commercially available AFB1-289 
resistant maize lines are yet available 54. Several cross bred maize lines were recently identified as 290 
resisting both AFB1 and FB1 contamination in field trials in South Africa, in which at least a few 291 
crosses were developed that did not accumulate AFB1 above 5 ppb or FB1 above 4 ppm (current 292 
regulatory levels) 55.  For DON in wheat, the quantitative trait locus Fhb1 permitted conjugation of 293 
DON with glucose and several glucose derivatives as well as glutathione conjugates, significantly 294 
increasing D3G/DON ratio 56. As noted in the above section on DON metabolism, this conversion 295 
would not be expected to significantly detoxify DON unless DON-de-epoxidating capability was 296 
also present in individuals ingesting this grain.  It might be presumed that any DON conjugate, 297 
whether with glucose, glutathione or other glucose derivatives would likely be deconjugated by gut 298 
bacteria, but that remains to be proven. Barley is another major source of DON; it has been 299 
discovered recently that black barley showed about half the DON contamination of yellow barley, 300 
so switching to this barley type might be a feasible mitigation approach 57.  A yeast species, 301 
Kluyveromyces thermotolerans was capable of decreasing OTA in grapes 58, which may be a 302 
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significant source of this toxin, so some types of biocontrol may be feasible, but will certainly need 303 
to be developed on a crop-specific basis. No work on OTA resistance in grain crop species was 304 
uncovered for this review.  But progress is being made, seemingly especially for AFB1 and FB1 305 
resistance in maize.    306 
A number of potential strategies to decrease mycotoxins during food processing have been 307 
demonstrated in the literature. Current US regulatory policies do not permit blending of a crop 308 
contaminated above key limits with non-contaminated crop; exceptions may be made when a 309 
severe mycotoxin contamination epidemic occurs. Diversion of mycotoxin contaminated crops 310 
into animal feeds may occur where regulatory levels permit46.   Regulators, scientists and citizens 311 
should engage in effective global discourse about the problem of mycotoxin contamination of 312 
crops used to feed humans.  It is important to determine a rational future for feeding a world in 313 
which mycotoxin contamination is likely to be a problem of increasing severity due to 314 
increasingly extreme weather and climate conditions that have been occurring and are predicted.  315 
More attention to development of low cost and effective means of decreasing mycotoxins in 316 
human foods as a part of food processing is warranted.   317 
Aflatoxin decontamination methods have been developed.  Screening grain kernels under UV 318 
light which can recognize grain grossly contaminated with aflatoxins and mechanical sorting to 319 
cull contaminated kernels is permitted in the US to achieve grain batches compliant with the 320 
action level for aflatoxin.  Ammoniation of cottonseed is permitted by FDA.  Although this 321 
method has been established to effectively detoxify maize containing aflatoxins59, with several 322 
trials across livestock and laboratory animals showing a reduction in aflatoxin content to 1% or 323 
less than in the starting contaminated grain59, this method is not approved for grains in the US.  324 
As summarized in a recent review focused on an African perspective on mycotoxin remediation 325 
60, sorting and cleaning before storage, and keeping stored grain dry may be quite effective in 326 
reducing aflatoxin contamination of grains and peanuts.  In a study using visibly moldy maize in 327 
Malawi, hand sorting to remove obviously damaged or shriveled seeds and seed fragments 328 
removed ~95% of AFB1 or FB1. Floating the kernels in water before sorting only removed about 329 
60% of either type of contamination; adding flotation to hand sorting showed no additional 330 
benefit61.  Thus, simple but labor intensive methods may be beneficial where farmers and 331 
consumers are educated about the health benefits of removing aflatoxins from foods. A novel 332 
method of treating hazelnuts with cold atmospheric plasma in a controlled pressure chamber 333 
using power of 1000 W decreased AFB1 content of the nuts by two-thirds after 12 min62.  This 334 
technique should not interfere with food quality and might be useful for many other AFB-335 
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containing foods.  The wider feasibility, mainly cost-effectiveness, of such technologies remains 336 
for future work. 337 
For DON, as might be expected from its hydrophilicity, processing foods in water such that the 338 
water is removed from the final product can remove significant amounts of DON.  This is 339 
pertinent but probably not practical for pasta. Boiling of 310 g pasta from 0-10 min showed 340 
progressive loss of DON from 0.62 ppm to 0.16 ppm (75% loss of DON)63, but as this was 341 
“fresh” pasta, eating quality would not be acceptable to many consumers after the longer boiling 342 
times that were more effective. Wheat flour bread making and baking did not diminish DON 343 
concentrations63.   Treatment of DON-contaminated dried distillers grain solids for nursery swine 344 
feed with 5% sodium metabisulfite,(SMB) autoclaving and drying decreased DON concentration 345 
in this feed by more than 80%.  Heating DON with SMB causes formation of a DON-10-346 
sulfonate, which was non-toxic to the pigs.  Average daily gain was restored to control levels by 347 
this treatment 64.  Practically, such treatments of grain flours for human intake might be feasible, 348 
but prevention of toxic effects to workers from sulfur dioxide gas release during processing 349 
would be important.  Also, some individuals may have allergic-like reactions to sulfites as food 350 
additives, and warning labels would be needed.  Heat processing per se, such as during extrusion 351 
of corn flour65 may remove DON by as much as 98%, but results from another lab with wheat 352 
flour did not show this ability of heat processing 66.  It seems prudent to conduct additional 353 
studies on SMB using human foods because this may be a cost-effective approach that could be 354 
necessary depending on the extent of DON contamination that may emerge in some regions.  355 
Additional investigations as to the potential of SMB treatment of DON contaminated grain flours 356 
to adversely affect sulfite sensitive individuals, and appropriate additional food labeling may be 357 
needed as well. 358 
Regulatory limits for ochratoxins in foods range from 2-10 ppb in the EU.  Pre-harvest control by 359 
good agricultural practices, careful use of fungicides and biocontrol agents (e.g., yeasts, 360 
natamycin) are thought to be most effective against OTA 67, as well as low-moisture storage.  361 
Adsorption of OTA from beverages may be feasible but must be evaluated carefully for effects on 362 
nutritional quality and taste; modified zeolites may be particularly useful67.  Quaternary 363 
ammonium beta-cyclodextrin was shown in vitro to have 200-fold stronger affinity for OTA than 364 
beta-cyclodextrin, as measured by fluorescent spectroscopic changes; this cyclodextrin derivative 365 
may be a good candidate for pass-through adsorption of OTA from beverages68.  More practical 366 
conditions will need to be investigated for such an adsorbent, as well as determination of any 367 
significant adverse effects on beverage quality from use of the adsorbent.  368 
13 
 
The prospect that human metabolic capabilities may also mitigate health risks from mycotoxins 369 
also deserves greater attention, based on the theoretical framework developed above (see section 370 
on mycotoxin metabolism).  371 
18.5 RECOMMENDATIONS 372 
Human risk assessment of mycotoxins that includes better recognition of disease and cost burdens 373 
of these food borne toxins is a primary need.  Such risk assessment should move toward 374 
incorporating the assessment of dietary and other health habits in addition to mycotoxin exposure 375 
assessment.  A number of dietary constituents, as discussed previously, might mitigate adverse 376 
effects of mycotoxins.  Exercise is increasingly recognized as a strong factor in mitigation of 377 
cancer risk69, but taking a global perspective, does intensive physical activity in the case of 378 
subsistence farmers confer benefits or add health stress? 379 
Discovery and development of mycotoxin resistant crop species is progressing.  This work will 380 
need to continue permanently as it is reasonable to consider that mycotoxigenic species will 381 
continue to evolve.  Integrated pest management systems that employ “green” technologies of 382 
biocontrol against mycotoxins must become feasible and affordable in the future. 383 
The recognition of the potential of microbes to degrade and detoxify mycotoxins may extend 384 
from the field to the fork, in that anti-mycotoxin microbes might be developed into a new 385 
generation of probiotics that could be incorporated into an array of ready-to-eat food products. 386 
Such a recommendation should be approached with great caution and respect for the many 387 
unknowns that need careful testing as fundamental discoveries move into product development.  388 
Engineering or manipulation of the human gut microbiome to contain microbes beyond what are 389 
naturally present across diverse human populations seems unwise without a great deal more 390 
understanding of gut microbial populations and interactions between these microbes and complex 391 
food constituents. 392 
A focus on extending adequate resources for mycotoxin management and mitigation to low 393 
income world regions must be the greatest priority.  Advances in the ability of human populations 394 
to effectively govern themselves and abide by fair rules of law will be needed to accomplish the 395 
needed eradication of excess liver cancer due to aflatoxin.  Humanity deserves better assurance of 396 
food safety; mycotoxins remain an important global consideration in that regard.   397 
Key words 398 
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